<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04804007</url>
  </required_header>
  <id_info>
    <org_study_id>CTO-IUSCCC-0742</org_study_id>
    <nct_id>NCT04804007</nct_id>
  </id_info>
  <brief_title>Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT</brief_title>
  <official_title>Randomized Phase 2 Trial of Maintenance Oral Etoposide or Observation Following High-dose Chemotherapy for Relapsed Metastatic Germ-Cell Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nabil Adra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label randomized phase II trial of maintenance oral etoposide vs. observation&#xD;
      in patinets with relapsed GCT treated with high-dose chemotherapy (HDCT) and peripheral-blood&#xD;
      stem-cell transplant (PBSCT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized phase 2 trial of maintenance etoposide versus observation following&#xD;
      HDCT+PBSCT for relapsed GCT. Patients who completed HDCT+PBSCT within the past 16 weeks will&#xD;
      enroll and randomize in 1:1 fashion to maintenance daily oral etoposide 50mg/m2 vs.&#xD;
      observation only.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients who completed HDCT+PBSCT within the past 16 weeks will enroll and randomize in 1:1 fashion to maintenance daily oral etoposide 50mg/m2 vs. observation only.&#xD;
Randomization will be stratified based on:&#xD;
-Presence of platinum refractory disease status defined by radiographic or serologic progression within 4 weeks of first-line cisplatin-based combination chemotherapy: yes vs. no</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12-month Progression Free Survival</measure>
    <time_frame>time from the date of randomization to the date of disease relapse or death (i.e. up to 1 year)</time_frame>
    <description>Investigator determination of tumor progression (clinical, radiographic, tumor markers including AFP and hCG)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>12-month Overall Survival</measure>
    <time_frame>Time of registration to death from any cause (i.e. up to 1 year)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess toxicity and tolerability of maintenance etoposide</measure>
    <time_frame>through study completion (i.e. up to 2 years)</time_frame>
    <description>Toxicities according to CTCAE v5 will be summarized by frequencies and rates calculated as the proportion of patients in the safety population experiencing SAEs, discontinuations due to AEs, and AEs.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Germ Cell Tumor</condition>
  <condition>Non-seminomatous Germ Cell Tumor</condition>
  <condition>Ovarian Germ Cell Tumor</condition>
  <arm_group>
    <arm_group_label>Maintenance Oral Etoposide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maintenance daily oral Etoposide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>If randomized to Observation, subjects will jump to follow-up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>etoposide will be provided with prescription for etoposide 50mg/m2 orally daily for 21 days out of 28 day cycles. Cycles will be repeated every 4 weeks for a total of 3 cycles.</description>
    <arm_group_label>Maintenance Oral Etoposide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent and HIPAA authorization for release of personal health&#xD;
             information&#xD;
&#xD;
          2. Age ≥ 18 years at the time of consent&#xD;
&#xD;
          3. Histological or serological evidence of non-seminomatous GCT&#xD;
&#xD;
          4. Relapsed disease after first-line cisplatin-based combination chemotherapy&#xD;
&#xD;
          5. Completed salvage treatment with HDCT and PBSCT for 2 tandem cycles per Institutional&#xD;
             Guidelines&#xD;
&#xD;
          6. HDCT must have been used as the initial salvage chemotherapy regimen (2nd line&#xD;
             therapy) 6.1. Note: 1 or 2 cycles of standard course regimens prior to HDCT are&#xD;
             acceptable (regimens include VeIP [vinblastine+ifosfmaide+cisplatin] or TIP&#xD;
             [paclitaxel+ifosfamide+cisplatin] or PVB [cisplatin+vinblastine+bleomycin]&#xD;
&#xD;
          7. Normal or declining tumor markers (AFP and hCG) at time of screening&#xD;
&#xD;
          8. Adverse events from prior therapy recovered to CTCAE v5.0 grade ≤ 2 at time of&#xD;
             registration&#xD;
&#xD;
          9. Women with ovarian germ cell tumors are eligible&#xD;
&#xD;
         10. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 within 28&#xD;
             days of study registration&#xD;
&#xD;
         11. Last dose of HDCT must be ≤16 weeks from study registration&#xD;
&#xD;
         12. Adequate organ function lab values obtained within 28 days prior to study registration&#xD;
             System Laboratory Value Hematological Absolute neutrophil count (ANC) ≥1,000 /mcL&#xD;
             Platelets ≥100,000 / mcL Hemoglobin ≥8 g/dL Renal Serum creatinine &lt;2mg/dL Hepatic&#xD;
             Serum total bilirubin ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for subjects with total&#xD;
             bilirubin levels &gt; 1.5 ULN&#xD;
&#xD;
             AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN OR&#xD;
&#xD;
               -  5 X ULN for subjects with liver metastases Coagulation International Normalized&#xD;
                  Ratio (INR) or Prothrombin Time (PT) ≤1.5 X ULN unless subject is receiving&#xD;
                  anticoagulant therapy as long as PT or PTT is within therapeutic range of&#xD;
                  intended use of anticoagulants Activated Partial Thromboplastin Time (aPTT) ≤1.5&#xD;
                  X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is&#xD;
                  within therapeutic range of intended use of anticoagulants&#xD;
&#xD;
         13. Male subjects should agree to use an adequate method of contraception starting with&#xD;
             the first dose of study therapy through 30 days after last dose of study therapy&#xD;
&#xD;
         14. If a female of childbearing potential, a negative urine pregnancy test within 28 days&#xD;
             prior to receiving the first dose of study drug.&#xD;
&#xD;
             o Non-childbearing potential is defined as (by other than medical reasons):&#xD;
&#xD;
               -  ≥ 45 years of age and has not had menses for &gt;2 years&#xD;
&#xD;
               -  Amenorrheic for &lt; 2 years without a hysterectomy and/or oophorectomy and a&#xD;
                  follicle-stimulating hormone value in the postmenopausal range upon pre-study&#xD;
                  (screening) evaluation&#xD;
&#xD;
               -  Post hysterectomy or oophorectomy. Documented hysterectomy or oophorectomy must&#xD;
                  be confirmed with medical records of the actual procedure or confirmed by an&#xD;
                  ultrasound.&#xD;
&#xD;
         15. For female patients of childbearing potential and male patients with partners of&#xD;
             childbearing potential, agreement (by patient and/or partner) to use two forms of&#xD;
             highly effective contraception (i.e., one that results in a low failure rate [&lt; 1% per&#xD;
             year] when used consistently and correctly) and to continue its use for 30 days after&#xD;
             the last dose of study therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Relapsed pure seminoma&#xD;
&#xD;
          2. Rising tumor markers (AFP and hCG) at time of screening&#xD;
&#xD;
          3. Patients who completed 2nd cycle of HDCT (time since last dose of HDCT) &gt;16 weeks ago&#xD;
&#xD;
          4. Treatment with any investigational agent within 28 days prior to study registration&#xD;
&#xD;
          5. Other active malignancy requiring treatment in past 12 months&#xD;
&#xD;
          6. History of psychiatric illness or social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          7. Active infection requiring systemic therapy&#xD;
&#xD;
          8. Previous hypersensitivity to etoposide which did not recover with supportive care&#xD;
&#xD;
          9. Pregnancy, lactation, or breastfeeding&#xD;
&#xD;
         10. Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the trial, interfere with the subject's&#xD;
             participation for the full duration of the trial, or is not in the best interest of&#xD;
             the subject to participate, in the opinion of the treating investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nabil Adra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christin Snow, RN</last_name>
    <phone>317-274-5830</phone>
    <email>chsnow@iu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Indiana University Melvin &amp; Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christin Snow, RN</last_name>
      <phone>317-274-5830</phone>
      <email>chsnow@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Nabil Adra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 15, 2021</study_first_submitted>
  <study_first_submitted_qc>March 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Nabil Adra</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Germ Cell Tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

